Significantly improved patient survival and time to recovery observed following the treatment, says Transcell Oncologics
A breakthrough human Umbilical Cord (UC) tissue harvested and clinically processed adult Mesenchymal Stem Cells (MSCs)-based therapy to COVID patients has been announced by Transcell Oncologics,
a biotech start-up company, incubated at ASPIRE-Technology Business Incubator (ASPIRE-TBI), University of Hyderabad (UoH) on Monday.
The firm had developed proprietary cell-based platform technology ‘HEMATO UC-MSCs’ with anti-cytokine storm properties, anti-inflammatory attributes and repairing abilities. The research recommends HEMATO UC-MSCs to be administered as “two intravenous infusions, at a dose of 100 million cells per infusion, given 72 hours apart to the COVID patients.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Resverlogix’s Apabetalone Demonstrates a Medical First in Patients with Chronic Kidney Disease
Resverlogix CorpApril 27, 2021 GMT
CALGARY, Alberta, April 27, 2021 (GLOBE NEWSWIRE) Resverlogix Corp. (“Resverlogix” or the “Company”) (TSX:RVX) announced today the recent publication of an article titled: “
Effect of Apabetalone on Major Adverse Cardiovascular Events in Patients with Chronic Kidney Disease, Type-2 Diabetes Mellitus and Recent Acute Coronary Syndrome: Results from the BETonMACE Randomized Controlled Trial ”, in the high-impact, peer-reviewed Clinical Journal of the American Society of Nephrology. The article was accompanied by a peer-reviewed editorial, published in the same journal, titled: “
Saxenda recommended for approval by European Medicines Agency committee for the treatment of obesity in adolescents aged 12-17 years finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Gap Between Oxford COVID Doses can be Increased to 3 Months by Angela Mohan on February 22, 2021 at 12:07 PM
The Lancet study.
According to the findings from a phase 3 randomized controlled trial, the first dose offered 76 per cent protection in the three months between doses.
The interval between doses can be safely extended to three months given the protection a single dose offers, which may allow countries to vaccinate a larger proportion of the population more rapidly, the researchers said. Where there is a limited supply, policies of initially vaccinating more people with a single dose may provide greater immediate population protection than vaccinating half the number of people with 2 doses, said lead author Andrew Pollard from the University of Oxford, UK.
For over two decades, society has been fighting a losing battle against the “epidemic of bullying.” Because we have come to rely on researchers for the solution, but researchers routinely recommend programs despite their poor results, I wrote a piece eight years ago called, “The First Step to Ending the Bullying Crisis.” It maintains that we will never turn the tide in this campaign until researchers begin questioning the bullying orthodoxy.
To my great excitement, a scholarly paper has been published that does exactly that. “Hypotheses for Possible Iatrogenic Impacts of School Bullying Prevention Programs,” by Karyn L. Healy, Ph.D., of the QIMR Berghofer Medical Research Institute, Australia, takes the bold step of highlighting findings that not only don’t most of the prevalent anti-bullying interventions work well, they may even be